Skip to content
MARKETS / BALCAO / LIFD
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Lftd Partners Inc. LIFD

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$36.9M
▼ 1.1% YoY
$-24.9M
$1.2M
Growth
USD 36.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 36.9 · Net income -24.9
20M40M-10M-20M201020122014201620182020202220242025
Compound annual growth
−13.7%
+47.2%
+14.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +47.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−67 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 2.5% · Net -67.3%
-500%201020122014201620182020202220242025
ROE
FY2025 · ROE -99.2%
-200%-400%201020122014201620182020202220242025

Each USD of equity lost 99 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 1.2
2.0M4.0M-0.5M-1.0M201020122014201620182020202220242025
Net buybacks $ Dividends $
FY2025 · Dividends — · Net buybacks 0.0
100000200000DividendsNet buybacks201320142019202020212022202320242025

Total assetsUSD 19.3M
EquityUSD 12.6M
CashUSD 1.8M
DepositsUSD 1.0M
Current ratio3.04×

Equity funds 66% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.10.10.00.00.0······0.00.00.0
Operating income $B0.0−0.00.00.00.0−0.0−0.0−0.0·····−0.0−0.0−0.0
EBITDA $B0.0−0.00.00.00.0−0.0−0.0······−0.0−0.0−0.0
Income tax $B0.0−0.00.0−0.00.00.0−0.00.00.00.00.00.00.0·0.00.0
Net income $B−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.00.00.0−0.0−0.0·······−0.0−0.0
EPS, diluted $−1.68−0.130.130.450.43−0.29−0.48−0.09−0.03−0.08−0.52−2.341.61−0.86−1.86−0.09
Dividend / sh $················
Payout %····0−1−0·········
ROE %−99.2−4.95.923.223.6−11.0−41.5···−189.2−410.0····
Shares out B0.010.010.010.010.010.010.000.000.000.000.000.000.000.000.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 74 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 21 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image